Regulatory ImpactRegulatory Impact
Insights

Research briefs for regulatory and competitive intelligence teams

Evidence-grounded market and regulatory briefs built for fast scanning, comparison, and strategic follow-up.

Oncology15 min read

Personalized mRNA Cancer Vaccines Move Into Pivotal Testing

Individualized mRNA vaccines have progressed from demonstrations of immune activation to randomized efficacy testing in resected cancer. Intismeran autogene leads the field, while autogene cevumeran and several early-stage platforms are testing whether the model can extend across tumors and development settings.

mRNAPersonalized Cancer VaccinesNeoantigens
Read Brief →

Stay ahead with new regulatory insights

Get new research briefs on product, target, and competitive landscapes as they publish.

Regulatory Strategy18 min read

Regulatory Lessons From Failed Alzheimer's Programs as of 2026

The lessons from failed Alzheimer's programs become clearer when read against the therapies that secured FDA approval. The resulting record shows that regulatory success depends on the complete alignment of mechanism, disease stage, exposure, biomarker strategy, clinical outcomes, safety, and approval pathway.

Alzheimer's diseaseFDAclinical development
Read Brief →
Cardiovascular Market Landscape9 min read

Hypertension Product Landscape in 2026: Baxfendy and Emerging Competition

Newly branded hypertension therapies are moving the category beyond traditional add-on sequencing. Baxfendy, Tryvio, lorundrostat, and zilebesiran illustrate an emerging split between approved oral options, pending class competition, and longer-horizon outcome-driven development.

Baxfendybaxdrostathypertension
Read Brief →
Cardiometabolic14 min read

Hyperlipidemia Treatment in 2026: Current Standards and the Next Wave of Lipid-Lowering Therapies

Hyperlipidemia care in 2026 is moving from a statin-centered sequence toward earlier combination therapy, injectable and RNA-based options, and risk-stratified treatment of LDL-C, triglycerides, familial syndromes, and Lp(a). The future pipeline is broad, but most late-stage innovation still depends on outcomes data and label-specific regulatory interpretation.

HyperlipidemiaDyslipidemiaLDL-C
Read Brief →